Septerna appointed Rajiv Patni as Chief Medical Officer effective August 24, 2026. Dr. Patni joins from Judo Bio, where he served as CEO, and brings over 25 years of experience in biopharmaceutical R&D and regulatory affairs. Septerna is a clinical-stage biotechnology company pioneering GPCR drug discovery.

Septerna, Inc. reported financial results for the second quarter ended June 30, 2026, on August 10, 2026. The company generated $26.7 million in revenue from its Novo Nordisk collaboration, compared to $0.1 million in the prior year period. Research and development expenses increased to $35.1 million from $22.2 million, while general and administrative expenses rose to $8.5 million from $6.9 million. The net loss for the quarter was $13.0 million, a significant improvement from the $24.8 million loss in the same period last year. Cash, cash equivalents, and marketable securities totaled $516.5 million as of June 30, 2026, with management expecting this runway to support operations at least into 2029. Pipeline updates highlighted ongoing Phase 1 trials for SEP-479, a PTH1R agonist for hypoparathyroidism, and continued development strategies for SEP-631 in mast cell-driven diseases. Septerna is a clinical-stage biotechnology company pioneering GPCR drug discovery to develop oral small molecule medicines.